NUMI Begins Appearing on Brokerages, Available for Pre-market Orders on Some

Post published:May 20, 2020
Post category:News

Numinus is set to trade publicly today, with many wondering how and when they can add a position in the company.

Earlier today, we shared some updates that suggest LKYSD may be the US OTC ticker for NUMI. Now, we have some further information on the NUMI ticker itself.

The below brokerages are in alphabetical order.

CIBC Investor’s Edge

You can call in orders via the phone, after which they should appear in your open orders where the parameters can be adjusted.

Degiro

We expect Degiro to list NUMI, as they offer access to the TSXV exchange.

E-Trade

E-Trade user have reported that they are able to place pre-market orders for LKYSD, which appears to be the US OTC stock for Numinus.

Fidelity

NUMI is showing up on Fidelity’s International Trade Portal as NUMI:CA. Pre-market orders appear to be unavailable.

Interactive Brokers

For our international readers, IB offers an excellent way to access foreign exchanges, like TSXV.

Interactive Brokers is accepting pre-market orders for NUMI here (you must be logged in to access this page).

Questrade

Unsurprisingly, this Canadian brokerage is taking pre-market orders for NUMI. You can find the trade page under the ticker NUMI.VN.

TD Ameritrade

NUMI is now appearing on TD Ameritrade (you may have to check the Advanced Dashboard) but is not open for pre-market orders.

More to Follow

We are no longer updating this page, as trading has now commenced.

You can follow us on Twitter for the latest.

Tags: Numinus

Real-World Data Reveals Variability in Access to, and Use of, SpravatoSeptember 13, 2024
While Janssen’s Spravato is on-track to become a blockbuster drug, access to the esketamine nasal spray product continues to be a key Acchiles heel for patients and their providers. Here, through study of two recent publications and interviews with their authors, we look at variability in access to, and real-world usage of, the therapy that psychedelic drug developers are increasingly hoping to imitate.
Pα+ Psychedelic Bulletin #172: Lykos Scales Back IIT Program, CEO Steps Down; Psyence Scoops Up Clairvoyant for Peanuts; Mindstate’s Moxy Enters Phase ISeptember 9, 2024
Lykos Scales Back Investigator-Initiated Trials Program, Refers Some Researchers to PharmAla • Lykos Appoints ‘Pharma Veterans’ to C-Suite • Psyence Scoops Up Clairvoyant for Peanuts • Mindstate’s Moxy Enters Phase I Trial • Embattled Braxia Bought for $180k • UK Gov. Unveils £400m Plan to Catalyse Clinical Trials • GH Research Waiting on Tox Studies to Respond to FDA’s Clinical Hold • Cydex Sues Bexson Over Psychedelic Salt Patents • and more...
Exclusive: David Hough on Lykos’ Path to ResubmissionSeptember 4, 2024
Josh sits down with the man drafted in by Lykos to plot a path to resubmitting its MDMA application. They talk about Hough’s experience in developing Spravato to eventual approval and how that might inform any future clinical development of MDMA, Hough’s thoughts about the FDA’s verdict and the AdComm that preceded it, what a future Phase 3 program might look like, and more…
Pα+ Psychedelic Bulletin #171: Lykos Criticises AdComm Process; Cybin’s Plan to Handle Functional Unblinding; Doblin Charts a Future for MAPS; DEA Plots Ketamine CrackdownAugust 30, 2024
Lykos CEO Provides AdComm Feedback to FDA Commissioner • Cybin Plans to Fight Functional Unblinding with ‘Firewall’ • Doblin Charts a Future for MAPS • DEA Plots Ketamine Crackdown • Colorado Closes First Round of Rulemaking for State Psychedelics Program • and more...
What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 2)August 28, 2024
In the second of a two-part series, we look at key trial design features FDA is expected to require of any future Phase 3 study from Lykos. Here, we run through how the MDMA drug developer will be expected to account for euphoria and other ‘positive’ adverse events, address selection bias, and favour larger academic and medical facilities as trial sites over private practices. What’s more, the company might be expected to outsource much of the trial's day-to-day operations.